scispace - formally typeset
X

Xinrong Tian

Researcher at GlaxoSmithKline

Publications -  28
Citations -  2435

Xinrong Tian is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Chemistry & Medicine. The author has an hindex of 6, co-authored 17 publications receiving 2113 citations.

Papers
More filters
Journal ArticleDOI

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.

TL;DR: GSK126, a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes and markedly inhibits the growth of EzH2 mutant DLBCL xenografts in mice are demonstrated.
Journal ArticleDOI

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.

TL;DR: A proliferation screen of cell lines representing a number of tumor types indicated that small cell lung carcinoma (SCLC) is sensitive to LSD1 inhibition, and a subset of SCLC lines and primary samples that undergo growth inhibition in response to GSK2879552 exhibit DNA hypomethylation of a signature set of probes, suggesting this may be used as a predictive biomarker of activity.
Patent

Cyclopropylamines as lsd1 inhibitors

TL;DR: In this article, the use of cyclopropylamine derivatives for modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1), was described.
Journal ArticleDOI

Electronically Engineering Water Resistance in Methane Combustion with an Atomically Dispersed Tungsten on PdO Catalyst.

TL;DR: In this paper , a stepwise strategy for the preparation of atomically dispersed tungsten species at the catalytically active site (Pd nanoparticles) is presented, after an activation process, a Pd-O-W1-like nanocompound is formed on the PdO surface with an atomic scale interface.